UBS Group
NVLN

UBS Group’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

UBS Group’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-3,823
Closed -$3K – 8788
2019
Q3 		$3K Buy
3,823
+2,157
+129% +$1.56K ﹤0.01% 7704
2019
Q2 		$1K Sell
1,666
-4,482
-73% -$4.99K ﹤0.01% 7802
2019
Q1 		$8K Buy
6,148
+5,641
+1,113% +$6.42K ﹤0.01% 6982
2018
Q4 		$0 Sell
507
-5,914
-92% -$6.68K ﹤0.01% 8524
2018
Q3 		$19K Buy
6,421
+4,464
+228% +$15.8K ﹤0.01% 6841
2018
Q2 		$7K Buy
1,957
+1,930
+7,148% +$7.75K ﹤0.01% 7373
2018
Q1 		$0 Sell
27
-697
-96% -$2.96K ﹤0.01% 8398
2017
Q4 		$2K Buy
724
+188
+35% +$904 ﹤0.01% 7661
2017
Q3 		$4K Buy
536
+509
+1,885% +$4.08K ﹤0.01% 7349
2017
Q2 		$0 Sell
27
-774
-97% -$7.45K ﹤0.01% 8198
2017
Q1 		$8K Sell
801
-925
-54% -$9.45K ﹤0.01% 6775
2016
Q4 		$14K Buy
+1,726
New +$15.3K ﹤0.01% 6744

Other funds holding NVLN

SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
FSA
Franklin Street Advisors Chapel Hill, North Carolina $1.79B AUM 28.1% 1-Year Est. Return

UBS Group's NVLN Position: Q4 2019 in Review

UBS Group sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q4 2019, closing a stake of 3,823 shares — an estimated $3K sold.

UBS Group first reported a position in NVLN in Q4 2016 and held it in 12 quarters. The position peaked at $19K in Q3 2018. 7 funds tracked by Wall St. Rank hold NVLN as of Q4 2019.

  • UBS Group reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q4 2019 after selling out during the quarter.
  • UBS Group sold 3,823 Novelion Therapeutics Inc. Common Shares shares in Q4 2019, an estimated $3K.
  • UBS Group first reported a position in Novelion Therapeutics Inc. Common Shares in Q4 2016 and held it in 12 quarters.
  • UBS Group's Novelion Therapeutics Inc. Common Shares position peaked at $19K in Q3 2018.
  • 7 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q4 2019.

Based on UBS Group's 13F filing for Q4 2019, filed 14 Feb 2020.